Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$26.71
+3.5%
$26.37
$12.00
▼
$30.74
$4.12B2.182.00 million shs2.33 million shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$326.62
-7.2%
$304.55
$146.20
▼
$379.63
$16.80B1.361.21 million shs1.73 million shs
Icon Plc stock logo
ICLR
Icon
$203.11
-0.3%
$173.91
$66.57
▼
$219.04
$15.60B1.191.17 million shs1.26 million shs
Revvity Inc. stock logo
RVTY
Revvity
$159.68
-2.3%
$146.58
$81.22
▼
$171.74
$18.24B1.081.82 million shs2.86 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
+3.53%-5.85%-10.49%+13.18%+57.86%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-6.76%-12.71%+5.08%+22.91%+83.13%
Icon Plc stock logo
ICLR
Icon
-0.32%-5.16%+20.66%+26.02%+24.64%
Revvity Inc. stock logo
RVTY
Revvity
-2.37%-3.41%+1.61%+39.38%+74.09%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$26.71
+3.5%
$26.37
$12.00
▼
$30.74
$4.12B2.182.00 million shs2.33 million shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$326.62
-7.2%
$304.55
$146.20
▼
$379.63
$16.80B1.361.21 million shs1.73 million shs
Icon Plc stock logo
ICLR
Icon
$203.11
-0.3%
$173.91
$66.57
▼
$219.04
$15.60B1.191.17 million shs1.26 million shs
Revvity Inc. stock logo
RVTY
Revvity
$159.68
-2.3%
$146.58
$81.22
▼
$171.74
$18.24B1.081.82 million shs2.86 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
+3.53%-5.85%-10.49%+13.18%+57.86%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-6.76%-12.71%+5.08%+22.91%+83.13%
Icon Plc stock logo
ICLR
Icon
-0.32%-5.16%+20.66%+26.02%+24.64%
Revvity Inc. stock logo
RVTY
Revvity
-2.37%-3.41%+1.61%+39.38%+74.09%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.63
Moderate Buy$30.0612.55% Upside
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.76
Moderate Buy$302.33-7.44% Downside
Icon Plc stock logo
ICLR
Icon
2.50
Moderate Buy$213.765.25% Upside
Revvity Inc. stock logo
RVTY
Revvity
2.32
Hold$133.86-16.17% Downside

Current Analyst Ratings Breakdown

Latest ADPT, RVTY, CRL, and ICLR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/4/2026
Revvity Inc. stock logo
RVTY
Revvity
Reiterated RatingNeutral
11/4/2026
Revvity Inc. stock logo
RVTY
Revvity
Boost Price TargetNeutral$155.00 ➝ $160.00
11/4/2026
Revvity Inc. stock logo
RVTY
Revvity
Boost Price TargetBuy$175.00 ➝ $185.00
11/4/2026
Revvity Inc. stock logo
RVTY
Revvity
Boost Price TargetEqual Weight$160.00 ➝ $175.00
11/4/2026
Revvity Inc. stock logo
RVTY
Revvity
Boost Price TargetSector Perform$135.00 ➝ $172.00
11/4/2026
Revvity Inc. stock logo
RVTY
Revvity
UpgradeHold ➝ Buy
11/2/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
DowngradeStrong-Buy ➝ Hold
10/30/2026
Icon Plc stock logo
ICLR
Icon
Set Price Target$228.00
10/29/2026
Icon Plc stock logo
ICLR
Icon
Reiterated RatingOutperform$235.00
10/29/2026
Icon Plc stock logo
ICLR
Icon
Reiterated RatingBuy$250.00
10/29/2026
Icon Plc stock logo
ICLR
Icon
Boost Price TargetOutperform$185.00 ➝ $226.00
(Data available from 11/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$308.08M13.84N/AN/A$1.47 per share18.17
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.02B3.88$20.38 per share16.03$64.39 per share5.07
Icon Plc stock logo
ICLR
Icon
$8.25B1.88$16.80 per share12.09$119.21 per share1.70
Revvity Inc. stock logo
RVTY
Revvity
$2.86B6.24$8.61 per share18.54$65.16 per share2.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$59.50M-$0.41N/AN/AN/A-20.73%-36.81%-13.77%N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-$144.34M-$4.85N/A25.963.29-5.96%15.75%6.51%N/A
Icon Plc stock logo
ICLR
Icon
$229.34M$5.8134.9619.1111.295.45%7.73%4.39%N/A
Revvity Inc. stock logo
RVTY
Revvity
$241.20M$2.1029.4626.972.958.61%8.64%5.24%N/A

Latest ADPT, RVTY, CRL, and ICLR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.10$0.02+$0.12$0.02$71.57 million$83.90 million
11/4/2026Q3 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.97$3.09+$0.12$6.86$960.36 million$982.73 million
11/3/2026Q3 2026
Revvity Inc. stock logo
RVTY
Revvity
$1.30$1.38+$0.08$0.56$694.73 million$728.90 million
10/27/2026Q3 2026
Icon Plc stock logo
ICLR
Icon
$2.62$2.66+$0.04$1.58$2.01 billion$2.02 billion
8/5/2026Q2 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.77$3.02+$0.25-$0.03$980.53 million$1.00 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
Revvity Inc. stock logo
RVTY
Revvity
$0.280.18%N/A13.33%N/A

Latest ADPT, RVTY, CRL, and ICLR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/30/2026
Revvity Inc. stock logo
RVTY
Revvity
quarterly$0.070.18%1/22/20271/22/20272/12/2027
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.22
4.79
4.68
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.92
1.35
1.04
Icon Plc stock logo
ICLR
Icon
0.37
1.32
1.32
Revvity Inc. stock logo
RVTY
Revvity
0.36
2.65
1.50

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Icon Plc stock logo
ICLR
Icon
95.61%
Revvity Inc. stock logo
RVTY
Revvity
86.65%

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
5.70%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Icon Plc stock logo
ICLR
Icon
44.00%
Revvity Inc. stock logo
RVTY
Revvity
0.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
624159.60 million150.50 millionOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
19,70047.74 million47.12 millionOptionable
Icon Plc stock logo
ICLR
Icon
40,10076.57 million42.88 millionOptionable
Revvity Inc. stock logo
RVTY
Revvity
11,000111.59 million110.64 millionOptionable

Recent News About These Companies

Revvity (NYSE:RVTY) Hits New 1-Year High on Better-Than-Expected Earnings
Revvity (NYSE:RVTY) Upgraded at Cfra
Earnings Beat Might Change The Case For Revvity (RVTY) Stock
Revvity (RVTY) Reaffirms Its Dividend, Is The Stock Now Too Pricey?
Revvity Q3 Earnings Call Highlights
Revvity Edges Past Q3 2026 Estimates, Posts $1.38 EPS, Revenue Up 4%
Revvity climbs 8% after Q3 results and raised guidance
Why is Revvity (RVTY) stock rocketing higher today
Revvity (RVTY) Q3 2026 Earnings Call Transcript
Revvity, Inc. (RVTY) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$26.71 +0.91 (+3.53%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$28.50 +1.79 (+6.71%)
As of 08:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$326.62 -25.25 (-7.18%)
Closing price 11/4/2026 03:59 PM Eastern
Extended Trading
$326.32 -0.31 (-0.09%)
As of 08:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Icon stock logo

Icon NASDAQ:ICLR

$203.11 -0.66 (-0.32%)
Closing price 11/4/2026 04:00 PM Eastern
Extended Trading
$202.74 -0.37 (-0.18%)
As of 08:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Revvity stock logo

Revvity NYSE:RVTY

$159.68 -3.81 (-2.33%)
Closing price 11/4/2026 03:59 PM Eastern
Extended Trading
$157.46 -2.21 (-1.39%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.